<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36750167</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-1802</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Matrix biology : journal of the International Society for Matrix Biology</Title><ISOAbbreviation>Matrix Biol</ISOAbbreviation></Journal><ArticleTitle>Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>66</EndPage><MedlinePgn>49-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.matbio.2023.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0945-053X(23)00011-2</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged as the cause of a global pandemic. Infection with SARS-CoV-2 can result in COVID-19 with both acute and chronic disease manifestations that continue to impact many patients long after the resolution of viral replication. There is therefore great interest in understanding the host factors that contribute to COVID-19 pathogenesis. In this review, we address the role of hyaluronan (HA), an extracellular matrix polymer with roles in inflammation and cellular metabolism, in COVID-19 and critically evaluate the hypothesis that HA promotes COVID-19 pathogenesis. We first provide a brief overview of COVID-19 infection. Then we briefly summarize the known roles of HA in airway inflammation and immunity. We then address what is known about HA and the pathogenesis of COVID-19 acute respiratory distress syndrome (COVID-19 ARDS). Next, we examine potential roles for HA in post-acute SARS-CoV-2 infection (PASC), also known as "long COVID" as well as in COVID-associated fibrosis. Finally, we discuss the potential therapeutics that target HA as a means to treat COVID-19, including the repurposed drug hymecromone (4-methylumbelliferone). We conclude that HA is a promising potential therapeutic target for the treatment of COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Henry W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirdjian</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddock</LastName><ForeName>Naomi L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaber</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Hunter A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karmouty-Quintana</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollyky</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Beckman Center, 279 Campus Drive, Stanford, CA 94305, USA. Electronic address: pbollyky@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DC019965</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL138510</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL148184</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL157100</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Matrix Biol</MedlineTA><NlmUniqueID>9432592</NlmUniqueID><ISSNLinking>0945-053X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9004-61-9</RegistryNumber><NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006820" MajorTopicYN="N">Hyaluronic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hyaluronan</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36750167</ArticleId><ArticleId IdType="pmc">PMC9899355</ArticleId><ArticleId IdType="doi">10.1016/j.matbio.2023.02.001</ArticleId><ArticleId IdType="pii">S0945-053X(23)00011-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.-.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki K., Fujiogi M., Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin. Immunol. 2020;215 doi: 10.1016/j.clim.2020.108427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108427</ArticleId><ArticleId IdType="pmc">PMC7169933</ArticleId><ArticleId IdType="pubmed">32325252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio. Medica Atenei Parmensis. 2020;91:157&#x2013;160. doi: 10.23750/abm.v91i1.9397.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Yang H., Ji W., Wu W., Chen S., Zhang W., Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372. doi: 10.3390/v12040372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12040372</ArticleId><ArticleId IdType="pmc">PMC7232198</ArticleId><ArticleId IdType="pubmed">32230900</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y.-.R., Cao Q.-.D., Hong Z.-.S., Tan Y.-.Y., Chen S.-.D., Jin H.-.J., Tan K.-.S., Wang D.-.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak &#x2013; an update on the status. Mil Med. Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00240-0</ArticleId><ArticleId IdType="pmc">PMC7068984</ArticleId><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>Platto S., Wang Y., Zhou J., Carafoli E. History of the COVID-19 pandemic: origin, explosion, worldwide spreading. Biochem. Biophys. Res. Commun. 2021;538:14&#x2013;23. doi: 10.1016/j.bbrc.2020.10.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.087</ArticleId><ArticleId IdType="pmc">PMC7834510</ArticleId><ArticleId IdType="pubmed">33199023</ArticleId></ArticleIdList></Reference><Reference><Citation>del Rio C., Omer S.B., Malani P.N. Winter of omicron&#x2014;the evolving COVID-19 pandemic. JAMA. 2022;327:319. doi: 10.1001/jama.2021.24315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24315</ArticleId><ArticleId IdType="pubmed">34935863</ArticleId></ArticleIdList></Reference><Reference><Citation>v Raveendran A., Jayadevan R., Sashidharan S. Long C.O.V.I.D.: an overview. Diabet. Metabol. Syndrome. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M., Dirksen A., Taraborrelli P., Torocastro M., Panagopoulos D., Sutton R., Lim P.B. Autonomic dysfunction in &#x2018;long COVID&#x2019;: rationale, physiology and management strategies. Clin. Med. 2021;21:e63&#x2013;e67. doi: 10.7861/clinmed.2020-0896.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer. 2004;4:528&#x2013;539. doi: 10.1038/nrc1391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1391</ArticleId><ArticleId IdType="pubmed">15229478</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent T.C., Laurent U.B., Fraser J.R.E. The structure and function of hyaluronan: an overview. Immunol. Cell Biol. 1996;74:a1&#x2013;a7. doi: 10.1038/icb.1996.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.1996.32</ArticleId><ArticleId IdType="pubmed">8724014</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Wang Y., Shao C., Huang J., Gan J., Huang X., Bucci E., Piacentini M., Ippolito G., Melino G. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451&#x2013;1454. doi: 10.1038/s41418-020-0530-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-0530-3</ArticleId><ArticleId IdType="pmc">PMC7091918</ArticleId><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellman U., Karlsson M.G., Engstr&#xf6;m-Laurent A., Cajander S., Dorofte L., Ahlm C., Laurent C., Blomberg A. Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options? J. Biol. Chem. 2020;295:15418&#x2013;15422. doi: 10.1074/jbc.AC120.015967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC120.015967</ArticleId><ArticleId IdType="pmc">PMC7650240</ArticleId><ArticleId IdType="pubmed">32978255</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson P., Arif A.A., Lee-Sayer S.S.M., Dong Y. Hyaluronan and its interactions with immune cells in the healthy and inflamed lung. Front. Immunol. 2018;9:2787. doi: 10.3389/fimmu.2018.02787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02787</ArticleId><ArticleId IdType="pmc">PMC6281886</ArticleId><ArticleId IdType="pubmed">30555472</ArticleId></ArticleIdList></Reference><Reference><Citation>Day A.J., Prestwich G.D. Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem. 2002;277:4585&#x2013;4588. doi: 10.1074/jbc.R100036200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R100036200</ArticleId><ArticleId IdType="pubmed">11717315</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637&#x2013;643. doi: 10.1016/j.it.2005.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2005.09.009</ArticleId><ArticleId IdType="pubmed">16214414</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbadi A., Lauer M., Swaidani S., Wang A., Hascall V. Hyaluronan rafts on airway epithelial cells. J. Biol. Chem. 2016;291:1448&#x2013;1455. doi: 10.1074/jbc.M115.704288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.704288</ArticleId><ArticleId IdType="pmc">PMC4714227</ArticleId><ArticleId IdType="pubmed">26601955</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Motte C.A., Hascall V.C., Drazba J., Bandyopadhyay S.K., Strong S.A. Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid. Am. J. Pathol. 2003;163:121&#x2013;133. doi: 10.1016/S0002-9440(10)63636-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63636-X</ArticleId><ArticleId IdType="pmc">PMC1868154</ArticleId><ArticleId IdType="pubmed">12819017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer M.E., Aytekin M., Comhair S.A., Loftis J., Tian L., Farver C.F., Hascall V.C., Dweik R.A. Modification of hyaluronan by heavy chains of inter-&#x3b1;-inhibitor in idiopathic pulmonary arterial hypertension. J. Biol. Chem. 2014;289:6791&#x2013;6798. doi: 10.1074/jbc.M113.512491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.512491</ArticleId><ArticleId IdType="pmc">PMC3945340</ArticleId><ArticleId IdType="pubmed">24403074</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrey A.C., de la Motte C.A. Thrombin cleavage of inter-&#x3b1;-inhibitor heavy chain 1 regulates leukocyte binding to an inflammatory hyaluronan matrix. J. Biol. Chem. 2016;291:24324&#x2013;24334. doi: 10.1074/jbc.M116.755660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.755660</ArticleId><ArticleId IdType="pmc">PMC5114391</ArticleId><ArticleId IdType="pubmed">27679489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa Y., He H., Mukai S., Imada T., Nakamura S., Su C.-.W., Mahabole M., Tseng S.C.G., Tsubota K. Heavy chain-hyaluronan/pentraxin 3 from amniotic membrane suppresses inflammation and scarring in murine lacrimal gland and conjunctiva of chronic graft-versus-host disease. Sci. Rep. 2017;7:42195. doi: 10.1038/srep42195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42195</ArticleId><ArticleId IdType="pmc">PMC5292704</ArticleId><ArticleId IdType="pubmed">28165063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord M.S., Melrose J., Day A.J., Whitelock J.M. The inter-&#x3b1;-trypsin inhibitor family: versatile molecules in biology and pathology. J. Histochem. Cytochem. 2020;68:907&#x2013;927. doi: 10.1369/0022155420940067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155420940067</ArticleId><ArticleId IdType="pmc">PMC7711241</ArticleId><ArticleId IdType="pubmed">32639183</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugg M.S., Willis A.C., Mukhopadhyay D., Hascall V.C., Fries E., F&#xfc;l&#xf6;p C., Milner C.M., Day A.J. Characterization of complexes formed between TSG-6 and inter-&#x3b1;-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan. J. Biol. Chem. 2005;280:25674&#x2013;25686. doi: 10.1074/jbc.M501332200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501332200</ArticleId><ArticleId IdType="pubmed">15840581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selbi W., de la Motte C.A., Hascall V.C., Day A.J., Bowen T., Phillips A.O. Characterization of hyaluronan cable structure and function in renal proximal tubular epithelial cells. Kidney Int. 2006;70:1287&#x2013;1295. doi: 10.1038/sj.ki.5001760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5001760</ArticleId><ArticleId IdType="pubmed">16900089</ArticleId></ArticleIdList></Reference><Reference><Citation>Evanko S.P., Potter-Perigo S., Johnson P.Y., Wight T.N. Organization of hyaluronan and versican in the extracellular matrix of human fibroblasts treated with the viral mimetic poly I:C. J. Histochem. Cytochem. 2009;57:1041&#x2013;1060. doi: 10.1369/jhc.2009.953802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/jhc.2009.953802</ArticleId><ArticleId IdType="pmc">PMC2762883</ArticleId><ArticleId IdType="pubmed">19581629</ArticleId></ArticleIdList></Reference><Reference><Citation>He H., Zhang S., Tighe S., Son J., Tseng S.C.G. Immobilized Heavy Chain-Hyaluronic Acid Polarizes Lipopolysaccharide-activated Macrophages toward M2 Phenotype. J. Biol. Chem. 2013;288:25792&#x2013;25803. doi: 10.1074/jbc.M113.479584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.479584</ArticleId><ArticleId IdType="pmc">PMC3764786</ArticleId><ArticleId IdType="pubmed">23878196</ArticleId></ArticleIdList></Reference><Reference><Citation>Day A.J., Milner C.M. TSG-6: a multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol. 2019;78&#x2013;79:60&#x2013;83. doi: 10.1016/j.matbio.2018.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2018.01.011</ArticleId><ArticleId IdType="pubmed">29362135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuipers H.F., Rieck M., Gurevich I., Nagy N., Butte M.J., Negrin R.S., Wight T.N., Steinman L., Bollyky P.L. Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization. Proc. Nat. Acad. Sci. 2016;113:1339&#x2013;1344. doi: 10.1073/pnas.1525086113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525086113</ArticleId><ArticleId IdType="pmc">PMC4747722</ArticleId><ArticleId IdType="pubmed">26787861</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang D., Liang J., Noble P.W. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011;91:221&#x2013;264. doi: 10.1152/physrev.00052.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00052.2009</ArticleId><ArticleId IdType="pmc">PMC3051404</ArticleId><ArticleId IdType="pubmed">21248167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy N., de la Zerda A., Kaber G., Johnson P.Y., Hu K.H., Kratochvil M.J., Yadava K., Zhao W., Cui Y., Navarro G., Annes J.P., Wight T.N., Heilshorn S.C., Bollyky P.L., Butte M.J. Hyaluronan content governs tissue stiffness in pancreatic islet inflammation. J. Biol. Chem. 2018;293:567&#x2013;578. doi: 10.1074/jbc.RA117.000148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA117.000148</ArticleId><ArticleId IdType="pmc">PMC5767862</ArticleId><ArticleId IdType="pubmed">29183997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollyky P.L., Falk B.A., Wu R.P., Buckner J.H., Wight T.N., Nepom G.T. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J. Leukoc Biol. 2009;86:567&#x2013;572. doi: 10.1189/jlb.0109001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0109001</ArticleId><ArticleId IdType="pmc">PMC2735281</ArticleId><ArticleId IdType="pubmed">19401397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollyky P.L., Lord J.D., Masewicz S.A., Evanko S.P., Buckner J.H., Wight T.N., Nepom G.T. Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4 + CD25 + regulatory T cells. J. Immunol. 2007;179:744&#x2013;747. doi: 10.4049/jimmunol.179.2.744.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.2.744</ArticleId><ArticleId IdType="pubmed">17617562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooki T., Murata-Kamiya N., Takahashi-Kanemitsu A., Wu W., Hatakeyama M. High-molecular-weight hyaluronan is a hippo pathway ligand directing cell density-dependent growth inhibition via PAR1b. Dev. Cell. 2019;49:590&#x2013;604.e9. doi: 10.1016/j.devcel.2019.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2019.04.018</ArticleId><ArticleId IdType="pubmed">31080060</ArticleId></ArticleIdList></Reference><Reference><Citation>Temple-Wong M.M., Ren S., Quach P., Hansen B.C., Chen A.C., Hasegawa A., D'Lima D.D., Koziol J., Masuda K., Lotz M.K., Sah R.L. Hyaluronan concentration and size distribution in human knee synovial fluid: variations with age and cartilage degeneration. Arthritis Res. Ther. 2016;18:18. doi: 10.1186/s13075-016-0922-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-0922-4</ArticleId><ArticleId IdType="pmc">PMC4721052</ArticleId><ArticleId IdType="pubmed">26792492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruppert S.M., Hawn T.R., Arrigoni A., Wight T.N., Bollyky P.L. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. Immunol. Res. 2014;58:186&#x2013;192. doi: 10.1007/s12026-014-8495-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8495-2</ArticleId><ArticleId IdType="pmc">PMC4106675</ArticleId><ArticleId IdType="pubmed">24614953</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J., Jiang D., Jung Y., Xie T., Ingram J., Church T., Degan S., Leonard M., Kraft M., Noble P.W. Role of hyaluronan and hyaluronan-binding proteins in human asthma. J. Allergy Clin. Immunol. 2011;128:403&#x2013;411.e3. doi: 10.1016/j.jaci.2011.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2011.04.006</ArticleId><ArticleId IdType="pmc">PMC3149736</ArticleId><ArticleId IdType="pubmed">21570715</ArticleId></ArticleIdList></Reference><Reference><Citation>Curk T., v Dubacheva G., Brisson A.R., Richter R.P. Controlling superselectivity of multivalent interactions with cofactors and competitors. J. Am. Chem. Soc. 2022;144:17346&#x2013;17350. doi: 10.1021/jacs.2c06942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c06942</ArticleId><ArticleId IdType="pmc">PMC9523699</ArticleId><ArticleId IdType="pubmed">36103600</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy N., Kuipers H.F., Marshall P.L., Wang E., Kaber G., Bollyky P.L. Hyaluronan in immune dysregulation and autoimmune diseases. Matrix Biol. 2019;78&#x2013;79:292&#x2013;313. doi: 10.1016/j.matbio.2018.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2018.03.022</ArticleId><ArticleId IdType="pmc">PMC6170738</ArticleId><ArticleId IdType="pubmed">29625181</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor K.R., Trowbridge J.M., Rudisill J.A., Termeer C.C., Simon J.C., Gallo R.L. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4 *. J. Biol. Chem. 2004;279:17079&#x2013;17084. doi: 10.1074/jbc.M310859200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310859200</ArticleId><ArticleId IdType="pubmed">14764599</ArticleId></ArticleIdList></Reference><Reference><Citation>Teder P., Vandivier R.W., Jiang D., Liang J., Cohn L., Pur&#xe9; E., Henson P.M., Noble P.W. Resolution of lung inflammation by CD44. Science. 1979;296(2002):155&#x2013;158. doi: 10.1126/science.1069659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1069659</ArticleId><ArticleId IdType="pubmed">11935029</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol. 2006;85:699&#x2013;715. doi: 10.1016/j.ejcb.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcb.2006.05.009</ArticleId><ArticleId IdType="pubmed">16822580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 2007;23:435&#x2013;461. doi: 10.1146/annurev.cellbio.23.090506.123337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.23.090506.123337</ArticleId><ArticleId IdType="pubmed">17506690</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor K.R., Yamasaki K., Radek K.A., di Nardo A., Goodarzi H., Golenbock D., Beutler B., Gallo R.L. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2. J. Biol. Chem. 2007;282:18265&#x2013;18275. doi: 10.1074/jbc.M606352200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M606352200</ArticleId><ArticleId IdType="pubmed">17400552</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Arif A., Olsson M., Cali V., Hardman B., Dosanjh M., Lauer M., Midura R.J., Hascall V.C., Brown K.L., Johnson P. Endotoxin free hyaluronan and hyaluronan fragments do not stimulate TNF-&#x3b1;, interleukin-12 or upregulate co-stimulatory molecules in dendritic cells or macrophages. Sci. Rep. 2016;6:36928. doi: 10.1038/srep36928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36928</ArticleId><ArticleId IdType="pmc">PMC5116629</ArticleId><ArticleId IdType="pubmed">27869206</ArticleId></ArticleIdList></Reference><Reference><Citation>Filion M.C., Phillips N.C. Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J. Pharm. Pharmacol. 2001;53:555&#x2013;561. doi: 10.1211/0022357011775677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/0022357011775677</ArticleId><ArticleId IdType="pubmed">11341374</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra S., Hascall V.C., Markwald R.R., Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front. Immunol. 2015;6 doi: 10.3389/fimmu.2015.00201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00201</ArticleId><ArticleId IdType="pmc">PMC4422082</ArticleId><ArticleId IdType="pubmed">25999946</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavianatou A.G., Caon I., Franchi M., Piperigkou Z., Galesso D., Karamanos N.K. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J. 2019;286:2883&#x2013;2908. doi: 10.1111/febs.14777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.14777</ArticleId><ArticleId IdType="pubmed">30724463</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwiniuk M., Krejner A., Speyrer M.S., Gauto A.R., Grzela T. Hyaluronic acid in inflammation and tissue regeneration. Wounds. 2016;28:78&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">26978861</ArticleId></ArticleIdList></Reference><Reference><Citation>Albtoush N., Petrey A.C. The role of hyaluronan synthesis and degradation in the critical respiratory illness COVID-19. Am. J. Physiol.-Cell Physiol. 2022;322:C1037&#x2013;C1046. doi: 10.1152/ajpcell.00071.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00071.2022</ArticleId><ArticleId IdType="pmc">PMC9126216</ArticleId><ArticleId IdType="pubmed">35442830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer M.E., Dweik R.A., Garantziotis S., Aronica M.A. The rise and fall of hyaluronan in respiratory diseases. Int. J. Cell Biol. 2015;2015:1&#x2013;15. doi: 10.1155/2015/712507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/712507</ArticleId><ArticleId IdType="pmc">PMC4581576</ArticleId><ArticleId IdType="pubmed">26448757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollyky P.L., Evanko S.P., Wu R.P., Potter-Perigo S., Long S.A., Kinsella B., Reijonen H., Guebtner K., Teng B., Chan C.K., Braun K.R., Gebe J.A., Nepom G.T., Wight T.N. Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse. Cell Mol. Immunol. 2010;7:211&#x2013;220. doi: 10.1038/cmi.2010.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2010.9</ArticleId><ArticleId IdType="pmc">PMC3027489</ArticleId><ArticleId IdType="pubmed">20228832</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell T.J., Brand O.J., Morgan D.J., Salek-Ardakani S., Jagger C., Fujimori T., Cholewa L., Tilakaratna V., &#xd6;stling J., Thomas M., Day A.J., Snelgrove R.J., Hussell T. Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biol. 2019;80:14&#x2013;28. doi: 10.1016/j.matbio.2018.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2018.06.006</ArticleId><ArticleId IdType="pmc">PMC6548309</ArticleId><ArticleId IdType="pubmed">29933044</ArticleId></ArticleIdList></Reference><Reference><Citation>Csoka A.B., Frost G.I., Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001;20:499&#x2013;508. doi: 10.1016/S0945-053X(01)00172-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0945-053X(01)00172-X</ArticleId><ArticleId IdType="pubmed">11731267</ArticleId></ArticleIdList></Reference><Reference><Citation>Queisser K.A., Mellema R.A., Middleton E.A., Portier I., Manne B.K., Denorme F., Beswick E.J., Rondina M.T., Campbell R.A., Petrey A.C. COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight. 2021;6 doi: 10.1172/jci.insight.147472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147472</ArticleId><ArticleId IdType="pmc">PMC8492325</ArticleId><ArticleId IdType="pubmed">34314391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoarau A., Polette M., Coraux C., Hyaluronasome Lung. Involvement of low molecular weight Ha (Lmw-Ha) in innate immunity. Biomolecules. 2022;12:658. doi: 10.3390/biom12050658.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12050658</ArticleId><ArticleId IdType="pmc">PMC9138743</ArticleId><ArticleId IdType="pubmed">35625586</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis S., Savani R.C. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019;78&#x2013;79:1&#x2013;10. doi: 10.1016/j.matbio.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2019.02.002</ArticleId><ArticleId IdType="pmc">PMC6774756</ArticleId><ArticleId IdType="pubmed">30802498</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammi M.I., Day A.J., Turley E.A. Hyaluronan and Homeostasis: a Balancing Act *. J. Biol. Chem. 2002;277:4581&#x2013;4584. doi: 10.1074/jbc.R100037200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R100037200</ArticleId><ArticleId IdType="pubmed">11717316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennon F.E., Singleton P.A. Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology. Am. J. Physiol.-Lung Cellular Mol. Physiol. 2011;301:L137&#x2013;L147. doi: 10.1152/ajplung.00071.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00071.2010</ArticleId><ArticleId IdType="pmc">PMC3154626</ArticleId><ArticleId IdType="pubmed">21571904</ArticleId></ArticleIdList></Reference><Reference><Citation>Dentener M.A. Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation. Thorax. 2005;60:114&#x2013;119. doi: 10.1136/thx.2003.020842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.2003.020842</ArticleId><ArticleId IdType="pmc">PMC1747307</ArticleId><ArticleId IdType="pubmed">15681498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormiston M.L., Slaughter G.R.D., Deng Y., Stewart D.J., Courtman D.W. The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension. Am. J. Physiol.-Lung Cellular Mol. Physiol. 2010;298:L148&#x2013;L157. doi: 10.1152/ajplung.00097.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00097.2009</ArticleId><ArticleId IdType="pubmed">19915162</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J., Zhang Y., Xie T., Liu N., Chen H., Geng Y., Kurkciyan A., Mena J.M., Stripp B.R., Jiang D., Noble P.W. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nat. Med. 2016;22:1285&#x2013;1293. doi: 10.1038/nm.4192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4192</ArticleId><ArticleId IdType="pmc">PMC5503150</ArticleId><ArticleId IdType="pubmed">27694932</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J., Jiang D., Noble P.W. Hyaluronan as a therapeutic target in human diseases. Adv. Drug. Deliv. Rev. 2016;97:186&#x2013;203. doi: 10.1016/j.addr.2015.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.10.017</ArticleId><ArticleId IdType="pmc">PMC4753080</ArticleId><ArticleId IdType="pubmed">26541745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Herrera J., Smith K., Yang L., Gilbertsen A., Benyumov A., Racila E., Bitterman P.B., Henke C.A. Hyaluronan/CD44 axis regulates S100A4-mediated mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2021;320:L926&#x2013;L941. doi: 10.1152/ajplung.00456.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00456.2020</ArticleId><ArticleId IdType="pmc">PMC8174831</ArticleId><ArticleId IdType="pubmed">33719561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kekevian A., Gershwin M.E., Chang C. Diagnosis and classification of idiopathic pulmonary fibrosis. Autoimmun. Rev. 2014;13:508&#x2013;512. doi: 10.1016/j.autrev.2014.01.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.01.037</ArticleId><ArticleId IdType="pubmed">24424167</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo P., Kropski J.A., Jones M.G., Lee J.S., Rossi G., Karampitsakos T., Maher T.M., Tzouvelekis A., Ryerson C.J. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol. Ther. 2021;222 doi: 10.1016/j.pharmthera.2020.107798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107798</ArticleId><ArticleId IdType="pmc">PMC8142468</ArticleId><ArticleId IdType="pubmed">33359599</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharaee-Kermani M., Phan S.H. Molecular Mechanisms of and Possible Treatment Strategies for Idiopathic Pulmonary Fibrosis. Curr. Pharm. Des. 2005;11:3943&#x2013;3971. doi: 10.2174/138161205774580561.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161205774580561</ArticleId><ArticleId IdType="pubmed">16305523</ArticleId></ArticleIdList></Reference><Reference><Citation>Antifibrotic therapy for the treatment of pulmonary fibrosis. Am. J. Med. Sci. 2001;322:213&#x2013;221. doi: 10.1097/00000441-200110000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000441-200110000-00012</ArticleId><ArticleId IdType="pubmed">11678519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjermer L., Lundgren R., H&#xe4;llgren R. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax. 1989;44:126&#x2013;131. doi: 10.1136/thx.44.2.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.44.2.126</ArticleId><ArticleId IdType="pmc">PMC461712</ArticleId><ArticleId IdType="pubmed">2928996</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jiang D., Liang J., Meltzer E.B., Gray A., Miura R., Wogensen L., Yamaguchi Y., Noble P.W. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J. Exp. Med. 2011;208:1459&#x2013;1471. doi: 10.1084/jem.20102510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20102510</ArticleId><ArticleId IdType="pmc">PMC3135364</ArticleId><ArticleId IdType="pubmed">21708929</ArticleId></ArticleIdList></Reference><Reference><Citation>Collum S.D., Chen N.-.Y., Hernandez A.M., Hanmandlu A., Sweeney H., Mertens T.C.J., Weng T., Luo F., Molina J.G., Davies J., Horan I.P., Morrell N.W., Amione-Guerra J., Al-Jabbari O., Youker K., Sun W., Rajadas J., Bollyky P.L., Akkanti B.H., Jyothula S., Sinha N., Guha A., Karmouty-Quintana H. Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis. Br. J. Pharmacol. 2017;174:3284&#x2013;3301. doi: 10.1111/bph.13947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13947</ArticleId><ArticleId IdType="pmc">PMC5595757</ArticleId><ArticleId IdType="pubmed">28688167</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng V., Collum S.D., Allawzi A., Crotty K., Yeligar S., Trammell A., Ryan Smith M., Kang B.-.Y., Sutliff R.L., Ingram J.L., Jyothula S.S.S.K., Thandavarayan R.A., Huang H.J., Nozik E.S., Wagner E.J., Michael Hart C. H. Karmouty-Quintana, 3&#x2019;UTR shortening of HAS2 promotes hyaluronan hyper-synthesis and bioenergetic dysfunction in pulmonary hypertension. Matrix Biol. 2022;111:53&#x2013;75. doi: 10.1016/j.matbio.2022.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2022.06.001</ArticleId><ArticleId IdType="pmc">PMC9676077</ArticleId><ArticleId IdType="pubmed">35671866</ArticleId></ArticleIdList></Reference><Reference><Citation>Collum S.D., Molina J.G., Hanmandlu A., Bi W., Pedroza M., Mertens T.C.J., Wareing N., Wei W., Wilson C., Sun W., Rajadas J., Bollyky P.L., Philip K.M., Ren D., Thandavarayan R.A., Bruckner B.A., Xia Y., Blackburn M.R., Karmouty-Quintana H. Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema. Dis. Model Mech. 2019;12 doi: 10.1242/dmm.038711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.038711</ArticleId><ArticleId IdType="pmc">PMC6550050</ArticleId><ArticleId IdType="pubmed">31036697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens T.C.J., Hanmandlu A., Tu L., Phan C., Collum S.D., Chen N.-.Y., Weng T., Davies J., Liu C., Eltzschig H.K., Jyothula S.S.K., Rajagopal K., Xia Y., Guha A., Bruckner B.A., Blackburn M.R., Guignabert C., Karmouty-Quintana H. Switching-Off Adora2b in vascular smooth muscle cells halts the development of pulmonary hypertension. Front. Physiol. 2018;9:555. doi: 10.3389/fphys.2018.00555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00555</ArticleId><ArticleId IdType="pmc">PMC5992271</ArticleId><ArticleId IdType="pubmed">29910735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Ling Y., Zhao F., Li W.W., Song Z., Wang L., Li Q., Liu M., Tong Y., Chen L., Ru D., Zhang T., Zhou K., Zhang B., Xu P., Yang Z., Li W.W., Song Y., Xu J., Zhu T., Shan F., Yu W., Lu H. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduct. Target Ther. 2022;7:1&#x2013;10. doi: 10.1038/s41392-022-00952-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00952-w</ArticleId><ArticleId IdType="pmc">PMC8931182</ArticleId><ArticleId IdType="pubmed">35304437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuipers H.F., Nagy N., Ruppert S.M., Sunkari V.G., Marshall P.L., Gebe J.A., Ishak H.D., Keswani S.G., Bollyky J., Frymoyer A.R., Wight T.N., Steinman L., Bollyky P.L. The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice. Clin. Exp. Immunol. 2016;185:372&#x2013;381. doi: 10.1111/cei.12815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12815</ArticleId><ArticleId IdType="pmc">PMC4991518</ArticleId><ArticleId IdType="pubmed">27218304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosser J.I., Nagy N., Goel R., Kaber G., Demirdjian S., Saxena J., Bollyky J.B., Frymoyer A.R., Pacheco-Navarro A.E., Burgener E.B., Rajadas J., Wang Z., Arbach O., Dunn C.E., Kalinowski A., Milla C.E., Bollyky P.L. Oral hymecromone decreases hyaluronan in human study participants. J. Clin. Investigat. 2022;132 doi: 10.1172/JCI157983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI157983</ArticleId><ArticleId IdType="pmc">PMC9057598</ArticleId><ArticleId IdType="pubmed">35499083</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J., Liu N., Liu X., Mena J.M., Xie T., Geng Y., Huan C., Zhang Y., Taghavifar F., Huang G., Kurkciyan A., Barron V., Jiang D., Noble P.W. Mitogen-activated protein kinase&#x2013;activated protein kinase 2 inhibition attenuates fibroblast invasion and severe lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2019;60:41&#x2013;48. doi: 10.1165/rcmb.2018-0033OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2018-0033OC</ArticleId><ArticleId IdType="pmc">PMC6348722</ArticleId><ArticleId IdType="pubmed">30130411</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito A.J., Bhatraju P.K., Stapleton R.D., Wurfel M.M., Mikacenic C. Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome. Crit. Care. 2017;21:304. doi: 10.1186/s13054-017-1895-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1895-7</ArticleId><ArticleId IdType="pmc">PMC5729515</ArticleId><ArticleId IdType="pubmed">29237497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonati C., Fumagalli J., Zanella A., Spinelli E., Mauri T. Hyaluronan in acute respiratory distress syndrome (ARDS): simply a biomarker or a deeper insight into ARDS mechanisms? J. Lab Precis. Med. 2018;3 doi: 10.21037/jlpm.2018.05.03. 49&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jlpm.2018.05.03</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai K.-.J., Spicer A.P., Mascarenhas M.M., Yu L., Ochoa C.D., Garg H.G., Quinn D.A. The role of hyaluronan synthase 3 in ventilator-induced lung injury. Am. J. Respir. Crit. Care Med. 2005;172:92&#x2013;98. doi: 10.1164/rccm.200405-652OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200405-652OC</ArticleId><ArticleId IdType="pmc">PMC2718450</ArticleId><ArticleId IdType="pubmed">15790861</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;llgren R., Samuelsson T., Laurent T.C., Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am. Rev. Respiratory Dis. 2012 doi: 10.1164/ajrccm/139.3.682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/139.3.682</ArticleId><ArticleId IdType="pubmed">2923370</ArticleId></ArticleIdList></Reference><Reference><Citation>Modig J., H&#xe4;llgren R. Increased hyaluronic acid production in lung &#x2014; a possible important factor in interstitial and alveolar edema during general anesthesia and in adult respiratory distress syndrome. Resuscitation. 1989;17:223&#x2013;231. doi: 10.1016/0300-9572(89)90038-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0300-9572(89)90038-5</ArticleId><ArticleId IdType="pubmed">2548268</ArticleId></ArticleIdList></Reference><Reference><Citation>McKallip R.J., Hagele H.F., Uchakina O.N. Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation. Toxins (Basel) 2013;5:1814&#x2013;1826. doi: 10.3390/toxins5101814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins5101814</ArticleId><ArticleId IdType="pmc">PMC3813913</ArticleId><ArticleId IdType="pubmed">24141285</ArticleId></ArticleIdList></Reference><Reference><Citation>McKallip R.J., Ban H., Uchakina O.N. Treatment with the Hyaluronic Acid Synthesis Inhibitor 4-Methylumbelliferone Suppresses LPS-Induced Lung Inflammation. Inflammation. 2015;38:1250&#x2013;1259. doi: 10.1007/s10753-014-0092-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-014-0092-y</ArticleId><ArticleId IdType="pubmed">25537799</ArticleId></ArticleIdList></Reference><Reference><Citation>Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66&#x2013;70. doi: 10.1016/j.cytogfr.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7204669</ArticleId><ArticleId IdType="pubmed">32418715</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak S.B., van Gool I.C., Cohen D., von der Th&#xfc;sen J.H., van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Modern Pathol. 2020;33:2128&#x2013;2138. doi: 10.1038/s41379-020-0603-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-020-0603-3</ArticleId><ArticleId IdType="pmc">PMC7306927</ArticleId><ArticleId IdType="pubmed">32572155</ArticleId></ArticleIdList></Reference><Reference><Citation>So M., Kabata H., Fukunaga K., Takagi H., Kuno T. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm. Med. 2021;21:97. doi: 10.1186/s12890-021-01463-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-021-01463-0</ArticleId><ArticleId IdType="pmc">PMC7983097</ArticleId><ArticleId IdType="pubmed">33752639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Poh C.M., R&#xe9;nia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020;20:363&#x2013;374. doi: 10.1038/s41577-020-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H., Neptune E., Cui H. Targeting ACE2 for COVID-19 Therapy: opportunities and Challenges. Am. J. Respir. Cell Mol. Biol. 2021;64:416&#x2013;425. doi: 10.1165/rcmb.2020-0322PS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2020-0322PS</ArticleId><ArticleId IdType="pmc">PMC8008810</ArticleId><ArticleId IdType="pubmed">33296619</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl T., Kaur I., Bungau S., Kumar A., Uddin M.S., Kumar C., Pal G., Shrivastava K., Zengin G., Arora S. The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sci. 2020;257 doi: 10.1016/j.lfs.2020.118075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118075</ArticleId><ArticleId IdType="pmc">PMC7347488</ArticleId><ArticleId IdType="pubmed">32653522</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendeiro A.F., Ravichandran H., Bram Y., Chandar V., Kim J., Meydan C., Park J., Foox J., Hether T., Warren S., Kim Y., Reeves J., Salvatore S., Mason C.E., Swanson E.C., Borczuk A.C., Elemento O., Schwartz R.E. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593:564&#x2013;569. doi: 10.1038/s41586-021-03475-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03475-6</ArticleId><ArticleId IdType="pmc">PMC8204801</ArticleId><ArticleId IdType="pubmed">33780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Batah S.S., Fabro A.T. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir. Med. 2021;176 doi: 10.1016/j.rmed.2020.106239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106239</ArticleId><ArticleId IdType="pmc">PMC7674971</ArticleId><ArticleId IdType="pubmed">33246294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonow R.O., Fonarow G.C., O'Gara P.T., Yancy C.W. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5:751. doi: 10.1001/jamacardio.2020.1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1105</ArticleId><ArticleId IdType="pubmed">32219362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., Miao X., Li Y., Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C., Duan C., Zhang S., Spiegel B., Shi H., Wang W., Zhang L., Lin R., Liu J., Ding Z., Hou X. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am. J. Gastroenterol. 2020;115:916&#x2013;923. doi: 10.14309/ajg.0000000000000664.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000664</ArticleId><ArticleId IdType="pmc">PMC7172493</ArticleId><ArticleId IdType="pubmed">32301761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q., Liu J., Liu Q., Kang L., Liu R., Jing W., Wu Y., Liu M. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis. JAMA Netw. Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.37257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.37257</ArticleId><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., v Madhavan M., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., Ahluwalia N., Bikdeli B., Dietz D., Der-Nigoghossian C., Liyanage-Don N., Rosner G.F., Bernstein E.J., Mohan S., Beckley A.A., Seres D.S., Choueiri T.K., Uriel N., Ausiello J.C., Accili D., Freedberg D.E., Baldwin M., Schwartz A., Brodie D., Garcia C.K., v Elkind M.S., Connors J.M., Bilezikian J.P., Landry D.W., Wan E.Y. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deeks S.G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43:268&#x2013;270. doi: 10.1016/j.it.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Callender L.A., Curran M., Bates S.M., Mairesse M., Weigandt J., Betts C.J. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front. Immunol. 2020;11 doi: 10.3389/fimmu.2020.01991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01991</ArticleId><ArticleId IdType="pmc">PMC7437504</ArticleId><ArticleId IdType="pubmed">32903476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovsyannikova I.G., Haralambieva I.H., Crooke S.N., Poland G.A., Kennedy R.B. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol. Rev. 2020;296:205&#x2013;219. doi: 10.1111/imr.12897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12897</ArticleId><ArticleId IdType="pmc">PMC7404857</ArticleId><ArticleId IdType="pubmed">32658335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross C.P., Essien U.R., Pasha S., Gross J.R., Wang S., Nunez-Smith M. Racial and ethnic disparities in population-level covid-19 mortality. J. Gen. Intern. Med. 2020;35:3097&#x2013;3099. doi: 10.1007/s11606-020-06081-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-06081-w</ArticleId><ArticleId IdType="pmc">PMC7402388</ArticleId><ArticleId IdType="pubmed">32754782</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A., Reed A.B., Ponzo S., Yassaee A., Aral M., Plans D., Labrique A., Mohan D. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021;16 doi: 10.1371/journal.pone.0247461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini J.J., Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323:2329&#x2013;2330. doi: 10.1001/jama.2020.6825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6825</ArticleId><ArticleId IdType="pubmed">32329799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratochvil M.J., Kaber G., Demirdjian S., Cai P.C., Burgener E.B., Nagy N., Barlow G.L., Popescu M., Nicolls M.R., Ozawa M.G., Regula D.P., Pacheco-Navarro A.E., Yang S., de Jesus Perez V.A., Karmouty-Quintana H., Peters A.M., Zhao B., Buja M.L., Johnson P.Y., Vernon R.B., Wight T.N., Milla C.E., Rogers A.J., Spakowitz A.J., Heilshorn S.C. P.L. Bollyky, Biochemical, biophysical, and immunological characterization of respiratory secretions in severe SARS-CoV-2 infections. JCI Insight. 2022;7 doi: 10.1172/jci.insight.152629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.152629</ArticleId><ArticleId IdType="pmc">PMC9309048</ArticleId><ArticleId IdType="pubmed">35730564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Dong C., Hu Y., Li C., Ren Q., Zhang X., Shi H., Zhou M. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: a Longitudinal Study. Radiology. 2020;296:E55&#x2013;E64. doi: 10.1148/radiol.2020200843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020200843</ArticleId><ArticleId IdType="pmc">PMC7233482</ArticleId><ArticleId IdType="pubmed">32191587</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., Xia P., Dong J., Zhao J., Wang F.-.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420&#x2013;422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams G.W., Berg N.K., Reskallah A., Yuan X., Eltzschig H.K. Acute respiratory distress syndrome. Anesthesiology. 2021;134:270&#x2013;282. doi: 10.1097/ALN.0000000000003571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000003571</ArticleId><ArticleId IdType="pmc">PMC7854846</ArticleId><ArticleId IdType="pubmed">33016981</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12 doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;Mechanisms, risk factors, and management. BMJ. 2021:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L., Tosto-Mancuso J., Wood J., Cortes M., Kontorovich A., McCarthy D., Rizk D., Mohammadi N., Breyman E., Nasr L., Kellner C., Putrino D. Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe acute infection. Rehab. Med. Phys. Therapy. 2020 http://medrxiv.org/lookup/doi/10.1101/2020.11.04.20226126</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.04.20226126</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer P.E., Kirwan J.P., Rosen C.J. Post-acute sequelae of COVID-19: a metabolic perspective. Elife. 2022;11:e78200. doi: 10.7554/eLife.78200.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.78200</ArticleId><ArticleId IdType="pmc">PMC8942467</ArticleId><ArticleId IdType="pubmed">35318939</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T.D., Finan B., Bloom S.R., D'Alessio D., Drucker D.J., Flatt P.R., Fritsche A., Gribble F., Grill H.J., Habener J.F., Holst J.J., Langhans W., Meier J.J., Nauck M.A., Perez-Tilve D., Pocai A., Reimann F., Sandoval D.A., Schwartz T.W., Seeley R.J., Stemmer K., Tang-Christensen M., Woods S.C., DiMarchi R.D., Tsch&#xf6;p M.H. Glucagon-like peptide 1 (GLP-1) Mol Metab. 2019;30:72&#x2013;130. doi: 10.1016/j.molmet.2019.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2019.09.010</ArticleId><ArticleId IdType="pmc">PMC6812410</ArticleId><ArticleId IdType="pubmed">31767182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E., Rusina P., Panova M., Novikov F., Grishagin I., Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals. 2021;14:807. doi: 10.3390/ph14080807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080807</ArticleId><ArticleId IdType="pmc">PMC8398080</ArticleId><ArticleId IdType="pubmed">34451904</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald L.T. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am. J. Physiol.-Lung Cellular Mol. Physiol. 2021;320:L257&#x2013;L265. doi: 10.1152/ajplung.00238.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00238.2020</ArticleId><ArticleId IdType="pmc">PMC7900916</ArticleId><ArticleId IdType="pubmed">33355522</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik B., Abdelazeem B., Ghatol A. Pulmonary fibrosis after COVID-19 pneumonia. Cureus. 2021:13. doi: 10.7759/cureus.13923.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.13923</ArticleId><ArticleId IdType="pmc">PMC8047761</ArticleId><ArticleId IdType="pubmed">33868858</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasarmidi E., Tsitoura E., Spandidos D.A., Tzanakis N., Antoniou K.M. Pulmonary fibrosis in the aftermath of the Covid-19 era (Review) Exp. Ther. Med. 2020;20:2557&#x2013;2560. doi: 10.3892/etm.2020.8980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.8980</ArticleId><ArticleId IdType="pmc">PMC7401793</ArticleId><ArticleId IdType="pubmed">32765748</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 2020;8:807&#x2013;815. doi: 10.1016/S2213-2600(20)30225-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30225-3</ArticleId><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambardar S.R., Hightower S.L., Huprikar N.A., Chung K.K., Singhal A., Collen J.F. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J. Clin. Med. 2021;10:2452. doi: 10.3390/jcm10112452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112452</ArticleId><ArticleId IdType="pmc">PMC8199255</ArticleId><ArticleId IdType="pubmed">34205928</ArticleId></ArticleIdList></Reference><Reference><Citation>Javaid H., Nigo M., Zhao B., Trujillo D.O., Hasbun R., Ostrosky-Zeichner L., Patel M., Jyothula S. Post-lung transplantation outcomes and ex vivo histopathological findings in severe post-Covid-19 pulmonary disease-a single-center experience. Open Forum Infect. Dis. 2022;9:ofac425. doi: 10.1093/ofid/ofac425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac425</ArticleId><ArticleId IdType="pmc">PMC9439573</ArticleId><ArticleId IdType="pubmed">36072698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharat A., Querrey M., Markov N.S., Kim S., Kurihara C., Garza-Castillon R., Manerikar A., Shilatifard A., Tomic R., Politanska Y., Abdala-Valencia H., v Yeldandi A., Lomasney J.W., v Misharin A., Budinger G.R.S. Lung transplantation for patients with severe COVID-19. Sci. Transl. Med. 2020;12:eabe4282. doi: 10.1126/scitranslmed.abe4282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe4282</ArticleId><ArticleId IdType="pmc">PMC8050952</ArticleId><ArticleId IdType="pubmed">33257409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharat A., Machuca T.N., Querrey M., Kurihara C., Garza-Castillon R., Kim S., Manerikar A., Pelaez A., Pipkin M., Shahmohammadi A., Rackauskas M., KG S.R., Balakrishnan K.R., Jindal A., Schaheen L., Hashimi S., Buddhdev B., Arjuna A., Rosso L., Palleschi A., Lang C., Jaksch P., Budinger G.R.S., Nosotti M., Hoetzenecker K. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir. Med. 2021;9:487&#x2013;497. doi: 10.1016/S2213-2600(21)00077-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00077-1</ArticleId><ArticleId IdType="pmc">PMC8012035</ArticleId><ArticleId IdType="pubmed">33811829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb M., Borensztajn K., Crestani B., Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers - insights from the bench side. Respiration. 2013;86:441&#x2013;452. doi: 10.1159/000357598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000357598</ArticleId><ArticleId IdType="pubmed">24356558</ArticleId></ArticleIdList></Reference><Reference><Citation>King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949&#x2013;1961. doi: 10.1016/S0140-6736(11)60052-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60052-4</ArticleId><ArticleId IdType="pubmed">21719092</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., v Colby T., Cordier J.-.F., Flaherty K.R., Lasky J.A., Lynch D.A., Ryu J.H., Swigris J.J., Wells A.U., Ancochea J., Bouros D., Carvalho C., Costabel U., Ebina M., Hansell D.M., Johkoh T., Kim D.S., King T.E., Kondoh Y., Myers J., M&#xfc;ller N.L., Nicholson A.G., Richeldi L., Selman M., Dudden R.F., Griss B.S., Protzko S.L., Sch&#xfc;nemann H.J., Statement An Official ATS/ERS/JRS/ALAT. Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011;183:788&#x2013;824. doi: 10.1164/rccm.2009-040GL.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.2009-040GL</ArticleId><ArticleId IdType="pmc">PMC5450933</ArticleId><ArticleId IdType="pubmed">21471066</ArticleId></ArticleIdList></Reference><Reference><Citation>Selman M., Pardo A. Alveolar epithelial cell disintegrity and subsequent activation. Am. J. Respir. Crit. Care Med. 2012;186:119&#x2013;121. doi: 10.1164/rccm.201206-0997ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201206-0997ED</ArticleId><ArticleId IdType="pubmed">22798412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cypel M., Keshavjee S. When to consider lung transplantation for COVID-19. Lancet Respir. Med. 2020;8:944&#x2013;946. doi: 10.1016/S2213-2600(20)30393-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30393-3</ArticleId><ArticleId IdType="pmc">PMC7447224</ArticleId><ArticleId IdType="pubmed">32857989</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli C., Piccarducci R., Marchetti L., Romei C., Martini C. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochem. Pharmacol. 2021;193 doi: 10.1016/j.bcp.2021.114812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2021.114812</ArticleId><ArticleId IdType="pmc">PMC8546906</ArticleId><ArticleId IdType="pubmed">34687672</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmouty-Quintana H., Thandavarayan R.A., Keller S.P., Sahay S., Pandit L.M., Akkanti B. Emerging mechanisms of pulmonary vasoconstriction in SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) and potential therapeutic targets. Int. J. Mol. Sci. 2020;21 doi: 10.3390/ijms21218081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218081</ArticleId><ArticleId IdType="pmc">PMC7662604</ArticleId><ArticleId IdType="pubmed">33138181</ArticleId></ArticleIdList></Reference><Reference><Citation>Potus F., Mai V., Lebret M., Malenfant S., Breton-Gagnon E., Lajoie A.C., Boucherat O., Bonnet S., Provencher S. Novel insights on the pulmonary vascular consequences of COVID-19. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020;319:L277&#x2013;L288. doi: 10.1152/ajplung.00195.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00195.2020</ArticleId><ArticleId IdType="pmc">PMC7414237</ArticleId><ArticleId IdType="pubmed">32551862</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan R.T., Gopalan D., Howard L., Vicente A., Park M., Manalan K., Wallner I., Marsden P., Dave S., Branley H., Russell G., Dharmarajah N., Kon O.M. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir. Med. 2021;9:107&#x2013;116. doi: 10.1016/S2213-2600(20)30407-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30407-0</ArticleId><ArticleId IdType="pmc">PMC7833494</ArticleId><ArticleId IdType="pubmed">33217366</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., v. Madhavan M., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., Ahluwalia N., Bikdeli B., Dietz D., Der-Nigoghossian C., Liyanage-Don N., Rosner G.F., Bernstein E.J., Mohan S., Beckley A.A., Seres D.S., Choueiri T.K., Uriel N., Ausiello J.C., Accili D., Freedberg D.E., Baldwin M., Schwartz A., Brodie D., Garcia C.K., v. Elkind M.S., Connors J.M., Bilezikian J.P., Landry D.W., Wan E.Y. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Larson C., Hammond T.C., Oronsky A., Kesari S., Lybeck M., Reid T.R. A review of persistent post-COVID syndrome (PPCS) Clin. Rev. Allergy Immunol. 2021 doi: 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Kream R.M., Stefano G.B. Long-term respiratory and neurological sequelae of COVID-19. Med. Sci. Monitor. 2020;26 doi: 10.12659/MSM.928996.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.928996</ArticleId><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>M.J. Kratochvil, G. Kaber, P.C. Cai, E.B. Burgener, G.L. Barlow, M.R. Nicolls, M.G. Ozawa, D.P. Regula, A.E. Pacheco-Navarro, C.E. Milla, N. Nagy, S. Yang, A.J. Rogers, A.J. Spakowitz, S.C. Heilshorn, P.L. Bollyky, Biochemical and Biophysical Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections, Infectious Diseases (except HIV/AIDS), 2020. http://medrxiv.org/lookup/doi/10.1101/2020.09.11.20191692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.11.20191692</ArticleId></ArticleIdList></Reference><Reference><Citation>M.J. Kratochvil, G. Kaber, S. Demirdjian, P.C. Cai, E.B. Burgener, N. Nagy, G.L. Barlow, M. Popescu, M.R. Nicolls, M.G. Ozawa, D.P. Regula, A.E. Pacheco-Navarro, S. Yang, V.A. de Jesus Perez, H. Karmouty-Quintana, A.M. Peters, B. Zhao, M.L. Buja, P.Y. Johnson, R.B. Vernon, T.N. Wight, C.E. Milla, A.J. Rogers, A.J. Spakowitz, S.C. Heilshorn, P.L. Bollyky, Biochemical, Biophysical, and Immunological Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections, Infectious Diseases (except HIV/AIDS), 2022. http://medrxiv.org/lookup/doi/10.1101/2022.03.28.22272848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.28.22272848</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlan A.N., Sutherland T.E., Marie C., Preissner S., Bradley B.T., Carpenter R.M., Sturek J.M., Ma J.Z., Moreau G.B., Donowitz J.R., Buck G.A., Serrano M.G., Burgess S.L., Abhyankar M.M., Mura C., Bourne P.E., Preissner R., Young M.K., Lyons G.R., Loomba J.J., Ratcliffe S.J., Poulter M.D., Mathers A.J., Day A.J., Mann B.J., Allen J.E., Petri W.A. Jr., IL-13 is a driver of COVID-19 severity. JCI Insight. 2021 doi: 10.1172/jci.insight.150107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.150107</ArticleId><ArticleId IdType="pmc">PMC8410056</ArticleId><ArticleId IdType="pubmed">34185704</ArticleId></ArticleIdList></Reference><Reference><Citation>Andonegui-Elguera S., Taniguchi-Ponciano K., Gonzalez-Bonilla C.R., Torres J., Mayani H., Herrera L.A., Pe&#xf1;a-Mart&#xed;nez E., Silva-Rom&#xe1;n G., Vela-Pati&#xf1;o S., Ferreira-Hermosillo A., Ramirez-Renteria C., Carvente-Garcia R., Mata-Lozano C., Marrero-Rodr&#xed;guez D., Mercado M. Molecular alterations prompted by SARS-CoV-2 infection: induction of hyaluronan, glycosaminoglycan and mucopolysaccharide metabolism. Arch. Med. Res. 2020;51:645&#x2013;653. doi: 10.1016/j.arcmed.2020.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.06.011</ArticleId><ArticleId IdType="pmc">PMC7301110</ArticleId><ArticleId IdType="pubmed">32611485</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvin M.R., Alvarez C., Miller J.I., Prates E.T., Walker A.M., Amos B.K., Mast A.E., Justice A., Aronow B., Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9:e59177. doi: 10.7554/eLife.59177.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59177</ArticleId><ArticleId IdType="pmc">PMC7410499</ArticleId><ArticleId IdType="pubmed">32633718</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski L.E., Menachery V.D. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12:135. doi: 10.3390/v12020135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12020135</ArticleId><ArticleId IdType="pmc">PMC7077245</ArticleId><ArticleId IdType="pubmed">31991541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding M., Zhang Q., Li Q., Wu T., Huang Y. Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. Respir. Med. 2020;167 doi: 10.1016/j.rmed.2020.105981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.105981</ArticleId><ArticleId IdType="pmc">PMC7167578</ArticleId><ArticleId IdType="pubmed">32421546</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama T., Yoshinaga S.K., Shibue K., Mak T.W. Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19. Cell Death Differ. 2021;28:3199&#x2013;3213. doi: 10.1038/s41418-021-00892-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00892-y</ArticleId><ArticleId IdType="pmc">PMC8522258</ArticleId><ArticleId IdType="pubmed">34663907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021;93:250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao N., Nie M., Pang H., Wang B., Hu J., Meng X., Li K., Ran X., Long Q., Deng H., Chen N., Li S., Tang N., Huang A., Hu Z. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat. Commun. 2021;12:1618. doi: 10.1038/s41467-021-21907-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21907-9</ArticleId><ArticleId IdType="pmc">PMC7955129</ArticleId><ArticleId IdType="pubmed">33712622</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., Aschenbrenner A.C. COVID-19 and the human innate immune system. Cell. 2021;184:1671&#x2013;1692. doi: 10.1016/j.cell.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.G., Simpson L.J., Ferreira A.-.M., Rustagi A., Roque J., Asuni A., Ranganath T., Grant P.M., Subramanian A., Rosenberg-Hasson Y., Maecker H.T., Holmes S.P., Levitt J.E., Blish C.A., Rogers A.J. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020;5 doi: 10.1172/jci.insight.140289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140289</ArticleId><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>K.E. Huntington, A.D. Louie, C.G. Lee, J.A. Elias, E.A. Ross, W.S. El-Deiry, Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2, Elife. 10 (2021) e64958. https://doi.org/10.7554/eLife.64958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7872512</ArticleId><ArticleId IdType="pubmed">33443016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser D.D., Cepinskas G., Slessarev M., Martin C., Daley M., Miller M.R., O'Gorman D.B., Gill S.E., Patterson E.K., dos Santos C.C. Inflammation profiling of critically ill coronavirus disease 2019 patients. Crit. Care Explor. 2020;2:e0144. doi: 10.1097/CCE.0000000000000144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000144</ArticleId><ArticleId IdType="pmc">PMC7314329</ArticleId><ArticleId IdType="pubmed">32696007</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchimido R., Schmidt E.P., Shapiro N.I. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit. Care. 2019;23:16. doi: 10.1186/s13054-018-2292-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2292-6</ArticleId><ArticleId IdType="pmc">PMC6337861</ArticleId><ArticleId IdType="pubmed">30654825</ArticleId></ArticleIdList></Reference><Reference><Citation>Goonewardena S.N., Grushko O.G., Wells J., Herty L., Rosenson R.S., Haus J.M., Hummel S.L. Immune-mediated glycocalyx remodeling in hospitalized COVID-19 patients. Cardiovasc. Drugs Ther. 2021 doi: 10.1007/s10557-021-07288-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-021-07288-7</ArticleId><ArticleId IdType="pmc">PMC8600103</ArticleId><ArticleId IdType="pubmed">34792686</ArticleId></ArticleIdList></Reference><Reference><Citation>Queisser K.A., Mellema R.A., Middleton E.A., Portier I., Manne B.K., Denorme F., Beswick E.J., Rondina M.T., Campbell R.A., Petrey A.C. COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight. 2021;6 doi: 10.1172/jci.insight.147472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147472</ArticleId><ArticleId IdType="pmc">PMC8492325</ArticleId><ArticleId IdType="pubmed">34314391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Wang T., Cai D., Hu Z., Chen J., Liao H., Zhi L., Wei H., Zhang Z., Qiu Y., Wang J., Wang A. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38&#x2013;42. doi: 10.1016/j.cytogfr.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7182527</ArticleId><ArticleId IdType="pubmed">32360420</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S., Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. J. Med. Virol. 2021;93:2735&#x2013;2739. doi: 10.1002/jmv.26826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26826</ArticleId><ArticleId IdType="pmc">PMC8014260</ArticleId><ArticleId IdType="pubmed">33506952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q., Wang B., Mao J. The pathogenesis and treatment of the `Cytokine Storm&#x2019; in COVID-19. J. Infect. 2020;80:607&#x2013;613. doi: 10.1016/j.jinf.2020.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.037</ArticleId><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ontong P., Prachayasittikul V. Unraveled roles of hyaluronan in severe COVID-19. EXCLI J. 2021;20:117&#x2013;125. doi: 10.17179/excli2020-3215.</Citation><ArticleIdList><ArticleId IdType="doi">10.17179/excli2020-3215</ArticleId><ArticleId IdType="pmc">PMC7868638</ArticleId><ArticleId IdType="pubmed">33564281</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigetti D., Genasetti A., Karousou E., Viola M., Moretto P., Clerici M., Deleonibus S., de Luca G., Hascall V.C., Passi A. Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the Nuclear Factor-&#x3ba;B (NF-&#x3ba;B) Pathway. J. Biol. Chem. 2010;285:24639&#x2013;24645. doi: 10.1074/jbc.M110.134536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.134536</ArticleId><ArticleId IdType="pmc">PMC2915700</ArticleId><ArticleId IdType="pubmed">20522558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao H.J., Wang H.-.S., Zhang Y., Lin H.-.Y., Phipps R.P., Smith T.J. Activation of Human Orbital Fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H Synthase-2 Expression. J. Biol. Chem. 1998;273:29615&#x2013;29625. doi: 10.1074/jbc.273.45.29615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.45.29615</ArticleId><ArticleId IdType="pubmed">9792671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardim-Santos G.P., Schulte H.L., Kurizky P.S., Gomes C.M., N&#xf3;brega O.T., de Gois E.T., de Carvalho M.R.M., Martins F.P., Nicola A.M., de Albuquerque C.P., Espindola L.S., Naves L.A., de S.M. Soares A.A., Albuquerque P., Fontes W., do Amaral L.R., de S. Gomes M., Bertarini P.L.L., Brito-de-Sousa J.P., Campi-Azevedo A.C., Peruhype-Magalh&#xe3;es V., Teixeira-Carvalho A., Valim V., Martins-Filho O.A., da Mota L.M.H. Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.1004023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1004023</ArticleId><ArticleId IdType="pmc">PMC9701840</ArticleId><ArticleId IdType="pubmed">36451835</ArticleId></ArticleIdList></Reference><Reference><Citation>Amer O.E., Sabico S., Sheshah E., Alotaibi N.H., Aldisi D.A., Enani M.A., Aljohani N.J., Alshingetti N., Alomar S.Y., Hussain S.D., Alnaami A.M., Elsaid M.A., Al-Daghri N.M. Evaluation of 34 cytokines and vitamin D status reveal a sexually-dimorphic active immune response to SARS-CoV-2. Healthcare. 2022;10:2571. doi: 10.3390/healthcare10122571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10122571</ArticleId><ArticleId IdType="pmc">PMC9778313</ArticleId><ArticleId IdType="pubmed">36554094</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz de Paula C.B., de Azevedo M.L.V., Nagashima S., Martins A.P.C., Malaquias M.A.S., dos S. Miggiolaro A.F.R., da Silva Motta J&#xfa;nior J., Avelino G., do Carmo L.A.P., Carstens L.B., de Noronha L. IL-4/IL-13 remodeling pathway of COVID-19 lung injury. Sci. Rep. 2020;10:18689. doi: 10.1038/s41598-020-75659-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75659-5</ArticleId><ArticleId IdType="pmc">PMC7596721</ArticleId><ArticleId IdType="pubmed">33122784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasson J., Donlan A.N., Ma J.Z., Haughey H.M., Coleman R., Nayak U., Mathers A.J., Laverdure S., Dewar R., Jackson P.E.H., Heysell S.K., Sturek J.M., Petri W.A. Safety and efficacy of dupilumab for the treatment of hospitalized patients with moderate to severe coronavirus disease 2019: a phase 2a trial. Open Forum. Infect. Dis. 2022;9:ofac343. doi: 10.1093/ofid/ofac343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac343</ArticleId><ArticleId IdType="pmc">PMC9361171</ArticleId><ArticleId IdType="pubmed">35959207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonser L.R., Eckalbar W.L., Rodriguez L., Shen J., Koh K.D., Ghias K., Zlock L.T., Christenson S., Woodruff P.G., Finkbeiner W.E., Erle D.J. The type 2 asthma mediator IL-13 inhibits severe acute respiratory syndrome coronavirus 2 infection of bronchial epithelium. Am. J. Respir. Cell Mol. Biol. 2022;66:391&#x2013;401. doi: 10.1165/rcmb.2021-0364OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2021-0364OC</ArticleId><ArticleId IdType="pmc">PMC8990122</ArticleId><ArticleId IdType="pubmed">34982656</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison C.B., Edwards C.E., Shaffer K.M., Araba K.C., Wykoff J.A., Williams D.R., Asakura T., Dang H., Morton L.C., Gilmore R.C., O'Neal W.K., Boucher R.C., Baric R.S., Ehre C. SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13. Proc. Nat. Acad. Sci. 2022;119 doi: 10.1073/pnas.2119680119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2119680119</ArticleId><ArticleId IdType="pmc">PMC9169748</ArticleId><ArticleId IdType="pubmed">35353667</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmouty-Quintana H., Xia Y., Blackburn M.R. Adenosine signaling during acute and chronic disease states. J. Mol. Med. (Berl) 2013;91:173&#x2013;181. doi: 10.1007/s00109-013-0997-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-013-0997-1</ArticleId><ArticleId IdType="pmc">PMC3606047</ArticleId><ArticleId IdType="pubmed">23340998</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmouty-Quintana H., Philip K., Acero L.F., Chen N.-.Y., Weng T., Molina J.G., Luo F., Davies J., Le N.-.B., Bunge I., Volcik K.A., Le T.-T.T., Johnston R.A., Xia Y., Eltzschig H.K., Blackburn M.R. Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J. 2015;29:50&#x2013;60. doi: 10.1096/fj.14-260182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-260182</ArticleId><ArticleId IdType="pmc">PMC4763976</ArticleId><ArticleId IdType="pubmed">25318478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tighe R.M., Garantziotis S. Hyaluronan interactions with innate immunity in lung biology. Matrix Biol. 2019;78&#x2013;79:84&#x2013;99. doi: 10.1016/j.matbio.2018.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2018.01.027</ArticleId><ArticleId IdType="pmc">PMC6072627</ArticleId><ArticleId IdType="pubmed">29410190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindra N.G., Alfajaro M.M., Gasque V., Habet V., Wei J., Filler R.B., Huston N.C., Wan H., Szigeti-Buck K., Wang B., Wang G., Montgomery R.R., Eisenbarth S.C., Williams A., Pyle A.M., Iwasaki A., Horvath T.L., Foxman E.F., Pierce R.W., van Dijk D., Wilen C.B. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium. Biorxiv. 2020 doi: 10.1101/2020.05.06.081695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.06.081695</ArticleId><ArticleId IdType="pmc">PMC8007021</ArticleId><ArticleId IdType="pubmed">33730024</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re'em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClin. Med. 2021;38 doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18 doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Carod Artal F.J. S&#xed;ndrome post-COVID-19: epidemiolog&#xed;a, criterios diagn&#xf3;sticos y mecanismos patog&#xe9;nicos implicados. Rev. Neurol. 2021;72:384. doi: 10.33588/rn.7211.2021230.</Citation><ArticleIdList><ArticleId IdType="doi">10.33588/rn.7211.2021230</ArticleId><ArticleId IdType="pubmed">34042167</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker A.M., Brigham E., Connolly B., McPeake J., v Agranovich A., Kenes M.T., Casey K., Reynolds C., Schmidt K.F.R., Kim S.Y., Kaplin A., Sevin C.M., Brodsky M.B., Turnbull A.E. Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respir. Med. 2021;9:1328&#x2013;1341. doi: 10.1016/S2213-2600(21)00385-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00385-4</ArticleId><ArticleId IdType="pmc">PMC8525917</ArticleId><ArticleId IdType="pubmed">34678213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Res Sq. 2021 doi: 10.21203/rs.3.rs-266574/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-266574/v1</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A., Collum S., Yuan X., Zhao B., Shivshankar P., Bi W., Buja L.M., Thandavarayan R., Huang H., Eltzschig H., Rosas I., de Frias F.P., Akkanti B., Jyothula S., Wareing N., Karmouty-Quintana H. Hyaluronan (HA) accumulation following SARS-CoV-2 infection and in non-resolvable COVID-19 fibrosis. ERJ Open Res. 2022;8 doi: 10.1183/23120541.LSC-2022.175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.LSC-2022.175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolesova O., Vanaga I., Laivacuma S., Derovs A., Kolesovs A., Radzina M., Platkajis A., Eglite J., Hagina E., Arutjunana S., Putrins D.S., Storozenko J., Rozentale B., Viksna L. Intriguing findings of liver fibrosis following COVID-19. BMC Gastroenterol. 2021;21:370. doi: 10.1186/s12876-021-01939-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-021-01939-7</ArticleId><ArticleId IdType="pmc">PMC8503733</ArticleId><ArticleId IdType="pubmed">34635073</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz de Paula C.B., Nagashima S., Liberalesso V., Collete M., da Silva F.P.G., Oricil A.G.G., Barbosa G.S., da Silva G.V.C., Wiedmer D.B., da Silva Dezid&#xe9;rio F., Noronha L. COVID-19: immunohistochemical analysis of TGF-&#x3b2; signaling pathways in pulmonary fibrosis. Int. J. Mol. Sci. 2021;23 doi: 10.3390/ijms23010168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010168</ArticleId><ArticleId IdType="pmc">PMC8745764</ArticleId><ArticleId IdType="pubmed">35008594</ArticleId></ArticleIdList></Reference><Reference><Citation>Evanko S.P., Potter-Perigo S., Petty L.J., Workman G.A., Wight T.N. Hyaluronan controls the deposition of fibronectin and collagen and modulates TGF-&#x3b2;1 induction of lung myofibroblasts. Matrix Biol. 2015;42:74&#x2013;92. doi: 10.1016/j.matbio.2014.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2014.12.001</ArticleId><ArticleId IdType="pmc">PMC4524654</ArticleId><ArticleId IdType="pubmed">25549589</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis S., Brezina M., Castelnuovo P., Drago L. The role of hyaluronan in the pathobiology and treatment of respiratory disease. Am. J. Physiol.-Lung Cellular Mol. Physiol. 2016;310:L785&#x2013;L795. doi: 10.1152/ajplung.00168.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00168.2015</ArticleId><ArticleId IdType="pmc">PMC4867348</ArticleId><ArticleId IdType="pubmed">26747781</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Li C., Zhang Y., He X., Chen X., Zeng X., Liu F., Chen Y., Chen J. Targeting mechanics-induced fibroblast activation through CD44-RhoA-YAP pathway ameliorates crystalline silica-induced silicosis. Theranostics. 2019;9:4993&#x2013;5008. doi: 10.7150/thno.35665.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.35665</ArticleId><ArticleId IdType="pmc">PMC6691376</ArticleId><ArticleId IdType="pubmed">31410197</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jiang D., Liang J., Meltzer E.B., Gray A., Miura R., Wogensen L., Yamaguchi Y., Noble P.W. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J. Experiment. Med. 2011;208:1459&#x2013;1471. doi: 10.1084/jem.20102510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20102510</ArticleId><ArticleId IdType="pmc">PMC3135364</ArticleId><ArticleId IdType="pubmed">21708929</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liang J., Yang T., Monterrosa Mena J., Huan C., Xie T., Kurkciyan A., Liu N., Jiang D., Noble P.W. Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis. Matrix Biol. 2016;55:35&#x2013;48. doi: 10.1016/j.matbio.2016.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2016.03.004</ArticleId><ArticleId IdType="pmc">PMC5383204</ArticleId><ArticleId IdType="pubmed">26987798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H.-.W., Lu C.-.J., Yu R.-.J., Hou X.-.M. An increase in hyaluronan by lung fibroblasts: a biomarker for intensity and activity of interstitial pulmonary fibrosis? Respirology. 1999;4:131&#x2013;138. doi: 10.1046/j.1440-1843.1999.00164.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1843.1999.00164.x</ArticleId><ArticleId IdType="pubmed">10382231</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y.M., Noureddin M., Liu C., Ohashi K., Kim S.Y., Ramnath D., Powell E.E., Sweet M.J., Roh Y.S., Hsin I.-.F., Deng N., Liu Z., Liang J., Mena E., Shouhed D., Schwabe R.F., Jiang D., Lu S.C., Noble P.W., Seki E. Hyaluronan synthase 2&#x2013;mediated hyaluronan production mediates Notch1 activation and liver fibrosis. Sci. Transl. Med. 2019;11 doi: 10.1126/scitranslmed.aat9284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aat9284</ArticleId><ArticleId IdType="pmc">PMC6589184</ArticleId><ArticleId IdType="pubmed">31189722</ArticleId></ArticleIdList></Reference><Reference><Citation>Collum S.D., Molina J.G., Hanmandlu A., Bi W., Pedroza M., Mertens T.C.J., Wareing N., Wei W., Wilson C., Sun W., Rajadas J., Bollyky P.L., Philip K.M., Ren D., Thandavarayan R.A., Bruckner B.A., Xia Y., Blackburn M.R., Karmouty-Quintana H. Adenosine and hyaluronan modulate lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema (CPFE) Dis. Model. Mech. 2019;12 doi: 10.1242/dmm.038711. dmm.038711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.038711</ArticleId><ArticleId IdType="pmc">PMC6550050</ArticleId><ArticleId IdType="pubmed">31036697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu S.C. Hyaluronic acid. Inflammation. 1980;4:107&#x2013;112. doi: 10.1007/BF00914107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00914107</ArticleId><ArticleId IdType="pubmed">7390611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara F., Granata G., Pelliccia C., la Porta R., Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. Eur. J. Clin. Pharmacol. 2020;76:1615&#x2013;1618. doi: 10.1007/s00228-020-02947-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-02947-4</ArticleId><ArticleId IdType="pmc">PMC7320911</ArticleId><ArticleId IdType="pubmed">32594204</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifirad S. Pirfenidone: a novel hypothetical treatment for COVID-19. Med. Hypotheses. 2020;144 doi: 10.1016/j.mehy.2020.110005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110005</ArticleId><ArticleId IdType="pmc">PMC7297676</ArticleId><ArticleId IdType="pubmed">32575019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata H., Nakagawa T., Sakoda S., Ishimatsu A., Taguchi K., Kadowaki M., Moriwaki A., Yoshida M. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019. Respirol. Case Rep. 2021;9 doi: 10.1002/rcr2.744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcr2.744</ArticleId><ArticleId IdType="pmc">PMC8008274</ArticleId><ArticleId IdType="pubmed">33815804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H., Zhang N., Liu Y., Yang X., He Y., Li Q., Shen X., Zhu Y., Yang Y. The interaction between pulmonary fibrosis and COVID-19 and the application of related anti-fibrotic drugs. Front. Pharmacol. 2022;12 doi: 10.3389/fphar.2021.805535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.805535</ArticleId><ArticleId IdType="pmc">PMC8766975</ArticleId><ArticleId IdType="pubmed">35069217</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura Y., Mitsuyama Y., Minami K., Nishida T., Watanabe A., Okada N., Yamakawa K., Nochioka K., Fujimi S. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study. Int. J. Infect. Dis. 2021;108:454&#x2013;460. doi: 10.1016/j.ijid.2021.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.05.055</ArticleId><ArticleId IdType="pmc">PMC8146615</ArticleId><ArticleId IdType="pubmed">34048887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kultti A., Pasonen-Sepp&#xe4;nen S., Jauhiainen M., Rilla K.J., K&#xe4;rn&#xe4; R., Py&#xf6;ri&#xe4; E., Tammi R.H., Tammi M.I. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp. Cell. Res. 2009;315:1914&#x2013;1923. doi: 10.1016/j.yexcr.2009.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2009.03.002</ArticleId><ArticleId IdType="pubmed">19285976</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahaffey C.L., Mummert M.E. Hyaluronan synthesis is required for IL-2-mediated T cell proliferation. J. Immunol. 2007;179:8191&#x2013;8199. doi: 10.4049/jimmunol.179.12.8191.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.12.8191</ArticleId><ArticleId IdType="pubmed">18056362</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy N., Freudenberger T., Melchior-Becker A., R&#xf6;ck K., ter Braak M., Jastrow H., Kinzig M., Lucke S., Suvorava T., Kojda G., Weber A.A., S&#xf6;rgel F., Levkau B., Erg&#xfc;n S., Fischer J.W. Inhibition of Hyaluronan Synthesis Accelerates Murine Atherosclerosis. Circulation. 2010;122:2313&#x2013;2322. doi: 10.1161/CIRCULATIONAHA.110.972653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.972653</ArticleId><ArticleId IdType="pubmed">21098434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003;4:33&#x2013;45. doi: 10.1038/nrm1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1004</ArticleId><ArticleId IdType="pubmed">12511867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber W., Carey V.J., Davis S., Hansen K.D., Morgan M. The Bioconductor channel in F1000Research. F1000Res. 2016 https://f1000research.com/articles/4-217</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786899</ArticleId><ArticleId IdType="pubmed">26998224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakizaki I., Kojima K., Takagaki K., Endo M., Kannagi R., Ito M., Maruo Y., Sato H., Yasuda T., Mita S., Kimata K., Itano N. A Novel Mechanism for the Inhibition of Hyaluronan Biosynthesis by 4-Methylumbelliferone. J. Biol. Chem. 2004;279:33281&#x2013;33289. doi: 10.1074/jbc.M405918200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M405918200</ArticleId><ArticleId IdType="pubmed">15190064</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigetti D., Rizzi M., Viola M., Karousou E., Genasetti A., Clerici M., Bartolini B., Hascall V.C., de Luca G., Passi A. The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells. Glycobiology. 2009;19:537&#x2013;546. doi: 10.1093/glycob/cwp022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwp022</ArticleId><ArticleId IdType="pubmed">19240269</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy N., Gurevich I., Kuipers H.F., Ruppert S.M., Marshall P.L., Xie B.J., Sun W., v Malkovskiy A., Rajadas J., Grandoch M., Fischer J.W., Frymoyer A.R., Kaber G., Bollyky P.L. 4-Methylumbelliferyl glucuronide contributes to hyaluronan synthesis inhibition. J. Biol. Chem. 2019;294:7864&#x2013;7877. doi: 10.1074/jbc.RA118.006166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006166</ArticleId><ArticleId IdType="pmc">PMC6514619</ArticleId><ArticleId IdType="pubmed">30914479</ArticleId></ArticleIdList></Reference><Reference><Citation>McKallip R., Hagele H., Uchakina O. Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation. Toxins (Basel) 2013;5:1814&#x2013;1826. doi: 10.3390/toxins5101814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins5101814</ArticleId><ArticleId IdType="pmc">PMC3813913</ArticleId><ArticleId IdType="pubmed">24141285</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves S.R., Barrow K.A., Rich L.M., White M.P., Shubin N.J., Chan C.K., Kang I., Ziegler S.F., Piliponsky A.M., Wight T.N., Debley J.S. Respiratory syncytial virus infection of human lung fibroblasts induces a hyaluronan-enriched extracellular matrix that binds mast cells and enhances expression of mast cell proteases. Front. Immunol. 2020;10:3159. doi: 10.3389/fimmu.2019.03159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.03159</ArticleId><ArticleId IdType="pmc">PMC6997473</ArticleId><ArticleId IdType="pubmed">32047499</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai E., Nishida Y., Wasa J., Urakawa H., Zhuo L., Kimata K., Kozawa E., Futamura N., Ishiguro N. Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br. J. Cancer. 2011;105:1839&#x2013;1849. doi: 10.1038/bjc.2011.459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2011.459</ArticleId><ArticleId IdType="pmc">PMC3251882</ArticleId><ArticleId IdType="pubmed">22045192</ArticleId></ArticleIdList></Reference><Reference><Citation>Collum S.D., Molina J.G., Hanmandlu A., Bi W., Pedroza M., Mertens T.C.J., Wareing N., Wei W., Wilson C., Sun W., Rajadas J., Bollyky P.L., Philip K.M., Ren D., Thandavarayan R.A., Bruckner B.A., Xia Y., Blackburn M.R., Karmouty-Quintana H. Adenosine and hyaluronan modulate lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema (CPFE) Dis. Model Mech. 2019 doi: 10.1242/dmm.038711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.038711</ArticleId><ArticleId IdType="pmc">PMC6550050</ArticleId><ArticleId IdType="pubmed">31036697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy N., Kuipers H.F., Frymoyer A.R., Ishak H.D., Bollyky J.B., Wight T.N., Bollyky P.L. 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front. Immunol. 2015;6 https://www.frontiersin.org/articles/10.3389/fimmu.2015.00123</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00123</ArticleId><ArticleId IdType="pmc">PMC4369655</ArticleId><ArticleId IdType="pubmed">25852691</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy N., Kaber G., Johnson P.Y., Gebe J.A., Preisinger A., Falk B.A., Sunkari V.G., Gooden M.D., Vernon R.B., Bogdani M., Kuipers H.F., Day A.J., Campbell D.J., Wight T.N., Bollyky P.L. Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis. J. Clin. Investigat. 2015;125:3928&#x2013;3940. doi: 10.1172/JCI79271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI79271</ArticleId><ArticleId IdType="pmc">PMC4607113</ArticleId><ArticleId IdType="pubmed">26368307</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall P.L., Nagy N., Kaber G., Barlow G.L., Ramesh A., Xie B.J., Linde M.H., Haddock N.L., Lester C.A., Tran Q.-.L., de Vries C.R., Hargil A., v Malkovskiy A., Gurevich I., Martinez H.A., Kuipers H.F., Yadava K., Zhang X., Evanko S.P., Gebe J.A., Wang X., Vernon R.B., de la Motte C., Wight T.N., Engleman E.G., Krams S.M., Meyer E.H., Bollyky P.L. Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection. Matrix Biol. 2021;96:69&#x2013;86. doi: 10.1016/j.matbio.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC8147171</ArticleId><ArticleId IdType="pubmed">33290836</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshioka Y., Kozawa E., Urakawa H., Arai E., Futamura N., Zhuo L., Kimata K., Ishiguro N., Nishida Y. Suppression of Hyaluronan Synthesis Alleviates Inflammatory Responses in Murine Arthritis and in Human Rheumatoid Synovial Fibroblasts. Arthritis Rheum. 2013;65:1160&#x2013;1170. doi: 10.1002/art.37861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37861</ArticleId><ArticleId IdType="pubmed">23335273</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter P., Seidel W. [Studies on the effect of 4-methyl-umbelliferon (Hymecromone) in patients following surgical revision of the biliary pathways] Chirurg. 1979;50:436&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">477470</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaranta S., Rossetti S., Camarri E. [Double-blind clinical study on hymecromone and placebo in motor disorders of the bile ducts after cholecystectomy] Clin. Ter. 1984;108:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">6233070</ArticleId></ArticleIdList></Reference><Reference><Citation>Camarri E., Marchettini G. [Hymecromone in the treatment of symptoms following surgery of the bile ducts] Recenti Prog. Med. 1988;79:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">3051197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann R.M., Schwarz G., Pohl C., Ziegenhagen D.J., Kruis W. [Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility] Dtsch. Med. Wochenschr. 2005;130:1938&#x2013;1943. doi: 10.1055/s-2005-872606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-872606</ArticleId><ArticleId IdType="pubmed">16123896</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabucchi E., Baratti C., Centemero A., Zuin M., Rizzitelli E., Colombo R. Controlled study of the effects of tiropramide on biliary dyskinesia. Pharmatherapeutica. 1986;4:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">2429334</ArticleId></ArticleIdList></Reference><Reference><Citation>Krawzak H.W., Heistermann H.P., Andrejewski K., Hohlbach G. Postprandial bile-duct kinetics under the influence of 4-methylumbelliferone (hymecromone) Int. J. Clin. Pharmacol. Ther. 1995;33:569&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">8574509</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S., Aburada M. The choleretic mechanism of coumarin compounds and phenolic compounds. J. Pharmacobiodyn. 1981;4:724&#x2013;734. doi: 10.1248/bpb1978.4.724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb1978.4.724</ArticleId><ArticleId IdType="pubmed">7334456</ArticleId></ArticleIdList></Reference><Reference><Citation>Garretta E..R., Venitz J. Comparisons of Detections, Stabilities, and Kinetics of Degradation of Hymecromone and Its Glucuronide and Sulfate Metabolites. J. Pharm. Sci. 1994;83:115&#x2013;116. doi: 10.1002/jps.2600830128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.2600830128</ArticleId><ArticleId IdType="pubmed">8138900</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett E.R., Venitz J., Eberst K., Cerda J.J. Pharmacokinetics and bioavailabilities of hymecromone in human volunteers. Biopharm. Drug Dispos. 1993;14:13&#x2013;39. doi: 10.1002/bdd.2510140103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdd.2510140103</ArticleId><ArticleId IdType="pubmed">8427942</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate A., Dimartino V., Spina P., Costa P.L., Lombardo C., Santini A., del Piano M., Alimonti P. Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, double-blind, placebo-controlled clinical study. Drugs Exp. Clin. Res. 2001;27:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">11951580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Ling Y., Zhao F., Li W., Song Z., Wang L., Li Q., Liu M., Tong Y., Chen L., Ru D., Zhang T., Zhou K., Zhang B., Xu P., Yang Z., Li W., Song Y., Xu J., Zhu T., Shan F., Yu W., Lu H. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduct. Target Ther. 2022;7:91. doi: 10.1038/s41392-022-00952-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00952-w</ArticleId><ArticleId IdType="pmc">PMC8931182</ArticleId><ArticleId IdType="pubmed">35304437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin B.K., Mucolytics Expectorants, Medications Mucokinetic. Respir. Care. 2007;52:859&#x2013;865. https://rc.rcjournal.com/content/52/7/859</Citation><ArticleIdList><ArticleId IdType="pubmed">17594730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson M., Sugumar K., Milan S.J., Hart A., Crockett A., Crossingham I. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2014;2018 doi: 10.1002/14651858.CD001289.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001289.pub2</ArticleId><ArticleId IdType="pmc">PMC6513404</ArticleId><ArticleId IdType="pubmed">24789119</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke M.O., Ratjen F. Mucolytics in cystic fibrosis. Paediatr. Respir. Rev. 2007;8:24&#x2013;29. doi: 10.1016/j.prrv.2007.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2007.02.009</ArticleId><ArticleId IdType="pubmed">17419975</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care. 2007;52:1176&#x2013;1197. https://rc.rcjournal.com/content/52/9/1176</Citation><ArticleIdList><ArticleId IdType="pubmed">17716385</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;iz Carro L., Mart&#xed;nez-Garc&#xed;a M.A. Use of Hyaluronic Acid (HA) in chronic airway diseases. Cells. 2020;9:2210. doi: 10.3390/cells9102210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9102210</ArticleId><ArticleId IdType="pmc">PMC7601363</ArticleId><ArticleId IdType="pubmed">33003557</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrigni G., Allegra L. Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma. Pulm. Pharmacol. Ther. 2006;19:166&#x2013;171. doi: 10.1016/j.pupt.2005.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2005.03.002</ArticleId><ArticleId IdType="pubmed">16406721</ArticleId></ArticleIdList></Reference><Reference><Citation>Furnari M.L., Termini L., Traverso G., Barrale S., Bonaccorso M.R., Damiani G., lo Piparo C., Collura M. Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study. Ther. Adv. Respir. Dis. 2012;6:315&#x2013;322. doi: 10.1177/1753465812458984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753465812458984</ArticleId><ArticleId IdType="pubmed">22968159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros M., Casciaro R., Lucca F., Troiani P., Salonini E., Favilli F., Quattrucci S., Sher D., Assael B.M. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. J. Aerosol. Med. Pulm. Drug Deliv. 2014;27:133&#x2013;137. doi: 10.1089/jamp.2012.1034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jamp.2012.1034</ArticleId><ArticleId IdType="pubmed">23745525</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi A., Castelnuovo P., Terranova P., Digilio E. Effects of sodium hyaluronate in children with recurrent upper respiratory tract infections: results of a randomised controlled study. Int. J. Immunopathol. Pharmacol. 2013;26:127&#x2013;135. doi: 10.1177/039463201302600112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463201302600112</ArticleId><ArticleId IdType="pubmed">23527715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantor J., Ma S., Turino G. A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017;12:2747&#x2013;2752. doi: 10.2147/COPD.S142156.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S142156</ArticleId><ArticleId IdType="pmc">PMC5609793</ArticleId><ArticleId IdType="pubmed">29075107</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdi F., Pedone C., McGee C.A., George M., Rice A.B., Hussain S.S., Vijaykumar K., Boitet E.R., Tearney G.J., McGrath J.A., Brown A.R., Rowe S.M., Incalzi R.A., Garantziotis S. Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study. Respir. Res. 2021;22:30. doi: 10.1186/s12931-020-01610-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01610-x</ArticleId><ArticleId IdType="pmc">PMC7847749</ArticleId><ArticleId IdType="pubmed">33517896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Z., Liao J., Cheong N., Longoria C., Cao G., DeLisser H.M., Savani R.C. The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury. Matrix Biol. 2019;78&#x2013;79:255&#x2013;271. doi: 10.1016/j.matbio.2018.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2018.08.002</ArticleId><ArticleId IdType="pmc">PMC6368477</ArticleId><ArticleId IdType="pubmed">30098420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman A., Cui Z., Foley J.P., Zhao H., Grimm P.C., DeLisser H.M., Savani R.C. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am. J. Respir. Cell Mol. Biol. 2005;33:447&#x2013;454. doi: 10.1165/rcmb.2004-0333OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2004-0333OC</ArticleId><ArticleId IdType="pmc">PMC2715352</ArticleId><ArticleId IdType="pubmed">16037485</ArticleId></ArticleIdList></Reference><Reference><Citation>Hut&#xe1;s G., Bajnok &#xc9;., G&#xe1;l I., Finnegan A., Glant T.T., Mikecz K. CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritis. Blood. 2008;112:4999&#x2013;5006. doi: 10.1182/blood-2008-04-150383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-04-150383</ArticleId><ArticleId IdType="pmc">PMC2597605</ArticleId><ArticleId IdType="pubmed">18815286</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>